Literature DB >> 7920658

Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism.

L Duprez1, J Parma, J Van Sande, A Allgeier, J Leclère, C Schvartz, M J Delisle, M Decoulx, J Orgiazzi, J Dumont.   

Abstract

The thyrotropin receptor (TSHR), a member of the large family of G protein-coupled receptors, controls both the function and growth of thyroid cells via stimulation of adenylyl cyclase. We report two different mutations in the TSHR gene of affected members of two large pedigrees with non-autoimmune autosomal dominant hyperthyroidism (toxic thyroid hyperplasia), that involve residues in the third (Val509Ala) and seventh (Cys672Tyr) transmembrane segments. When expressed by transfection in COS-7 cells, the mutated receptors display a higher constitutive activation of adenylyl cyclase than wild type. This new disease entity is the germline counterpart of hyperfunctioning thyroid adenomas, in which different somatic mutations with similar functional characteristics have been demonstrated.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7920658     DOI: 10.1038/ng0794-396

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  57 in total

1.  Systematic identification of mutations that constitutively activate the angiotensin II type 1A receptor by screening a randomly mutated cDNA library with an original pharmacological bioassay.

Authors:  C Parnot; S Bardin; S Miserey-Lenkei; D Guedin; P Corvol; E Clauser
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

Review 2.  Thyrotropin receptor mutations in thyroid diseases.

Authors:  P M Yen
Journal:  Rev Endocr Metab Disord       Date:  2000-01       Impact factor: 6.514

3.  Subclinical nonautoimmune hyperthyroidism in a family segregates with a thyrotropin receptor mutation with weakly increased constitutive activity.

Authors:  Eijun Nishihara; Chun-Rong Chen; Takuya Higashiyama; Yumiko Mizutori-Sasai; Mitsuru Ito; Sumihisa Kubota; Nobuyuki Amino; Akira Miyauchi; Basil Rapoport
Journal:  Thyroid       Date:  2010-10-07       Impact factor: 6.568

Review 4.  The PTH/PTHrP receptor in Jansen's metaphyseal chondrodysplasia.

Authors:  L M Calvi; E Schipani
Journal:  J Endocrinol Invest       Date:  2000-09       Impact factor: 4.256

5.  Familial nontoxic multinodular thyroid goiter locus maps to chromosome 14q but does not account for familial nonmedullary thyroid cancer.

Authors:  G R Bignell; F Canzian; M Shayeghi; M Stark; Y Y Shugart; P Biggs; J Mangion; R Hamoudi; J Rosenblatt; P Buu; S Sun; S S Stoffer; D E Goldgar; G Romeo; R S Houlston; S A Narod; M R Stratton; W D Foulkes
Journal:  Am J Hum Genet       Date:  1997-11       Impact factor: 11.025

6.  Ras homolog enriched in striatum inhibits the functional activity of wild type thyrotropin, follicle-stimulating hormone, luteinizing hormone receptors and activating thyrotropin receptor mutations by altering their expression in COS-7 cells.

Authors:  P Agretti; G De Marco; A Pinchera; P Vitti; J Bernal; M Tonacchera
Journal:  J Endocrinol Invest       Date:  2007-04       Impact factor: 4.256

Review 7.  Fetal neonatal hyperthyroidism: diagnostic and therapeutic approachment.

Authors:  Selim Kurtoğlu; Ahmet Özdemir
Journal:  Turk Pediatri Ars       Date:  2017-03-01

Review 8.  Thyrotropin receptor-associated diseases: from adenomata to Graves disease.

Authors:  Terry F Davies; Takao Ando; Reigh-Yi Lin; Yaron Tomer; Rauf Latif
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

9.  Similarities and differences in the phenotype of members of an Italian family with hereditary non-autoimmune hyperthyroidism associated with an activating TSH receptor germline mutation.

Authors:  F Arturi; E Chiefari; S Tumino; D Russo; S Squatrito; G Chazenbalk; L Persani; B Rapoport; S Filetti
Journal:  J Endocrinol Invest       Date:  2002-09       Impact factor: 4.256

10.  A monoclonal antibody with thyrotropin (TSH) receptor inverse agonist and TSH antagonist activities binds to the receptor hinge region as well as to the leucine-rich domain.

Authors:  Chun-Rong Chen; Sandra M McLachlan; Basil Rapoport
Journal:  Endocrinology       Date:  2009-03-19       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.